US98887Q1040
© BusinessWire
08.12.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified a...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Updates to China’s National Reimbursement Drug List
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA):
VYVGART® (efgartigimod alfa injection) is renewed for the treatment of adult patients with generalize...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2025, along with recent product highlights and corporate updates.
“Zai Lab is entering the next phase of our growth, powered by the rapid advancement of our global pipeline and supported by a commercially profitable and scalable business in China...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
31.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in Investor Conferences in November and December 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2025:
Jefferies Global Healthcare Conference in London
Fireside Chat: Wednesday, November 19, 2025 at 8:30AM GMT
Location: London
Citi's 2025 Global Heal...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
24.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
Conference Call and Webcas...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets an...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
“Today’s approval of TIVDAK marks an important milestone for Za...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in Investor Conferences in September 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2025:
Cantor Global Healthcare Conference
Presentation: Thursday, September 4, 2025, 10:20 a.m. ET
Location: New York, NY
Morgan Stanley 23rd Annual Global Healthcar...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
ZLAB
LISTED
NASDAQ
Zai Lab Establishes Oncology Scientific Advisory Board
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is comprised of distinguished oncology leaders and will support the advancement of the Company’s robust oncology products and pipeline, including multiple internally developed investigational therap...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
ZLAB
LISTED
NASDAQ
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both fe...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
17.07.2025
ZLAB
LISTED
NASDAQ
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both fe...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2025 financial results and provide recent corporate updates on August 7, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT).
Conference Call and Webcast...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.
Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaning...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
ZLAB
LISTED
NASDAQ
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings, featured during a poster present...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
ZLAB
LISTED
NASDAQ
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company’s potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
ZLAB
LISTED
NASDAQ
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Cli...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in Investor Conferences in June 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in June 2025:
Jefferies Global Healthcare Conference
Fireside Chat: Wednesday, June 4, 2025, 10:30 a.m. EST
Webcast Link: https://wsw.com/webcast/jeff319/zlab/1845848
Location: Ne...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
ZLAB
LISTED
NASDAQ
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company’s potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2025, along with recent product highlights and corporate updates.
“In the first quarter, we continued to advance both our global pipeline and commercial business,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are rapidly ex...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
ZLAB
LISTED
NASDAQ
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, a...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company’s potential first-in-class and best-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), wil...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended...
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2025 financial results and provide recent corporate updates on May 8, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT).
Conference Call and Webcast...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunothe...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
“In China...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in Investor Conferences in March 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in March 2025:
Leerink Partners 2025 Global Healthcare Conference
Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST
Location: Miami, FL
Jefferies Biotech on the Beach Summit
T...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates.
“2024 was a defining year for Zai Lab, marked by strong sales growth, financial strength, and significant pipeline progress. As we look ahead, 2025 is set to be a tran...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC).
“Receiving an Orphan Drug Designation for ZL-1310 recognizes...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults.
“There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful improvement in overall survival with TIVDAK treatment for patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy....
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
News Preview
Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a rec...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.
Th...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in Investor Conference in January 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2025:
43rd Annual J.P. Morgan Healthcare Conference
Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST
Location: San Francisco
A live webcast of the presentation wi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
ZLAB
LISTED
NASDAQ
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
News Preview
Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with ge...
Themefolio
Profiler
Peergroup
© BusinessWire
28.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications:
AUGTYRO® (repotrectinib) is included in the NRDL for the treatment of adult patients with loc...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
News Preview
Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in main...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
News Preview
Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
News Preview
Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS.
The gross proce...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Proposed Public Offering of American Depositary Shares
News Preview
Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $200.0 million of American depositary shares (“ADSs”), each representing ten ordinary shares of the Company with a par value of $0.000006 per sh...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates.
“In the third quarter, we delivered strong commercial results, maintained financial discipline, and continued to advance our global pipeline of innovative medicines,” said Dr. Sam...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult pa...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
ZLAB
LISTED
NASDAQ
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT (xanomeline and trospium chloride) in China. Consistent with previous global studies, the registrational bridging trial met its primary endpoint, with KarXT demonstrating a st...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
ZLAB
LISTED
NASDAQ
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC), at the EORTC-NCI-AACR (ENA) Symposium 2024 in Barcelona, Spain, as an oral presentation during the plenary session. ZL-1310 is being tested in patients with p...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in November and December Investor Conferences
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2024:
Goldman Sachs APAC Healthcare Corporate Day 2024
Time: November 5-8, 2024
Location: Hong Kong, Hong Kong
Jefferies London Healthcare Conference
Fir...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
ZLAB
LISTED
NASDAQ
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company’s investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
ZLAB
LISTED
NASDAQ
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2024 and recent corporate updates, before the opening of the U.S. equity markets on Tuesday, November 12, 2024. The Company will host a live conference call and webcast on the same date, at 8:00 a.m. ET (9:00 p.m. HKT).
Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
ZLAB
LISTED
NASDAQ
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a Phase 1 study of ZL-1310, the Company’s investigational antibody-drug conjugate (ADC), will be presented during a plenary session at the EORTC-NCI-AACR Symposium (ENA) 2024 taking place October 23-25, in Barcelona, Spain. The preliminary results from the ongoing...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
ZLAB
LISTED
NASDAQ
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a preclinical study of ZL-1503, the company’s internally discovered IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
ZLAB
LISTED
NASDAQ
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from a Phase 1 study of ZL-1218, the company’s anti-CCR8 antibody, will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13-17, 2024, in Barcelona, Spain. The preliminary results from the ongoing dose-escala...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in September Investor Conferences
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2024:
Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, New York
Cantor Fitzgerald Global Healthcare Conference
Fireside Chat: Thursday,...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
